Equillium is a biotechnology company developing products for autoimmune and inflammatory disorders and immuno-inflammation. The Company’s first product candidate, EQ001, is a clinical-stage monoclonal antibody that targets the immune receptor CD6. It plays a central role in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus and multiple sclerosis.
|HQ||San Diego, US||Map|
|Employees (est.) (Jun 2019)||16||(+7%)|
|Share Price (May 2020)||$3.5||(+6%)|
Net income (Q1, 2020)
EBIT (Q1, 2020)
Market capitalization (27-May-2020)
Closing stock price (27-May-2020)
When was Equillium founded?
Equillium was founded in 2017.
Who are Equillium key executives?
Equillium's key executives are Krishna Polu, Jason Keyes and Joel Rothman.
How many employees does Equillium have?
Equillium has 16 employees.
Who are Equillium competitors?
Competitors of Equillium include Tridek-One, Arog Pharmaceuticals and InDevR.
Where is Equillium headquarters?
Equillium headquarters is located at 2223 Avenida De La Playa #108, La Jolla, San Diego.
Where are Equillium offices?
Equillium has an office in San Diego.
How many offices does Equillium have?
Equillium has 1 office.
Receive alerts for 300+ data fields across thousands of companies